spacer
home > ebr > spring 2018 > editors letter
PUBLICATIONS
European Biopharmaceutical Review

Editors Letter

Cannabis and its potential for medicinal use has made press headlines again recently; a young boy from the UK with a rare form of epilepsy who appeared to respond well to an experimental cannabis-based treatment in the Netherlands has triggered a consideration for a formal clinical trial in the UK to more fully investigate its potential in this patient. An often cited and significant body of anecdotal evidence exists that suggests cannabis-based products have benefits in epilepsy and a range of other medical conditions including the control of pain in cancer patients, management of symptoms in multiple sclerosis, etc – the common thread being neurological disorders. In 2017, an 11-year-old boy was allowed access to prescribed cannabis oil in the UK for life-threatening severe epilepsy and the clinical benefit to this young patient undoubtedly sets something of a precedent for its investigation in the six-year-old with a rarer form of epilepsy.

What will the impact for the biopharmaceutical industry be if and when large clinical trials begin for products based on this potent, naturally derived product and its subsequent (potentially) introduction to clinical practice? Its production, regulation, and control (quality, legal, and otherwise) will, no doubt, throw up new and unique challenges. However, if the end result benefits patients with safe medicinal products based on cannabis, then these will undoubtedly be worthwhilechallenges to tackle and overcome.

Migraine is one of the neurological disorders for which cannabis has been reported as having clinical advantage, although, as with epilepsy, this is yet to be confirmed by larger clinical studies. Migraine is a complex condition, and, despite being the most common debilitating neurological disease, Professor Dr Uwe Reuter at Charité Universitätsmedizin explains that therapy options have not advanced to any significant degree until recently (page 18). Thanks to progress in better understanding migraine pathophysiology, new approaches are tackling migraine and specifically the application of Onabotulinum toxin A that reduces plasma levels of calcitonin gene-related peptide (CGRP) and the now advanced clinical development of biological approaches; antibodies against the CGRP receptor (Erenumab) and ligand (galcanezumab, fremanezumab, and eptinezumab) could represent major breakthroughs in migraine treatment and help significant numbers of future patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O'Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Appoints Lawrence Miller as Chief Technology Officer

LONDON & PHILADELPHIA – June 13, 2019: Signant Health, formerly CRF Bracket, has appointed Lawrence Miller as Chief Technology Officer. Signant unites electronic Clinical Outcomes Assessment (eCOA), eConsent, Patient Engagement, Interactive Response Technology (IRT), Clinical Supply Management and Endpoint Quality into the industry’s most comprehensive patient-centric suite of technology solutions and services. An accomplished innovator, Miller brings unique vision and expertise to a Signant team already committed to advancing clinical research with its next-generation technology portfolio.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement